Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | HTR5A | P47898 | 6/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16373144 | 0.77 | ABCB1 (0.47) | ESR1SLC6A4HTR5AABCB1ABCG2 | |
| SCHEMBL21012023 | 0.76 | ESR1 (0.58) | ESR1KDM4EALDH1A1ABCG2MAPT | |
| SCHEMBL23793705 | 0.76 | ESR1 (0.58) | ESR1KDM4EALDH1A1ABCG2MAPT | |
| SCHEMBL13877241 | 0.69 | SLC6A4 (0.47) | SLC6A4HTR5AKDM4EALDH1A1ABCB1 | |
| SCHEMBL24443798 | 0.67 | ESR1 (0.54) | ESR1KDM4EALDH1A1ABCB1ABCG2 | |
| SCHEMBL26424146 | 0.67 | ESR1 (0.67) | ESR1 | |
| Palazestrant SCHEMBL23280512 | 0.66 | ESR1 (0.78) | ESR1 | |
| Palazestrant SCHEMBL24885107 | 0.66 | ESR1 (0.78) | ESR1 | |
| Palazestrant SCHEMBL20528170 | 0.66 | ESR1 (0.78) | ESR1 | |
| Palazestrant SCHEMBL30128723 | 0.66 | ESR1 (0.78) | ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129598-A1 | METHODS OF TREATING ESTROGEN RECEPTOR-ASSOCIATED DISEASES | OLEMA PHARMACEUTICALS, INC. | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129598-A1 | METHODS OF TREATING ESTROGEN RECEPTOR-ASSOCIATED DISEASES | ESRRB, ESRRG, ESRRA | ESR1 6/4885SLC6A4 2019/4885HDAC6 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.